Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
September 5, 2024
Latest announcements
Announcement type:
Search Announcements 
Sensitive
Year:
| Price Sensitive |
Latest announcements
Announcement type:
Search Announcements
Sensitive
Year:
| Price Sensitive |
About Prescient Therapeutics
Prescient Therapeutics develops personalised therapies to conquer cancer. It has a broad portfolio of well advanced assets developed with world-leading partners including Yale, UPenn, Oxford, Moffitt & Peter MacCallum.
Prescient’s first in class targeted therapy – PTX-100 – is currently in clinical development and showing encouraging activity in diseases of unmet need.
Prescient also owns the exclusive rights to two next generation cell therapy platform technologies, OmniCAR and CellPryme – both with the potential to enhance cell therapies and overcome challenges faced by current generation approaches – effectively giving Prescient a ‘shovels to the gold rush’ advantage in this burgeoning area of cancer treatment.
8th April, 2022
Watch this 5-minute video to hear from CEO Michael Davidson to learn more about:
- How Prescienttherapeutics has accelerated its growth through partnerships with industry leaders Square, Stripe and Zip
- How the company’s pure tech approach and first-mover advantage is disrupting the SME finance market with more than 1.25 million potential customers
- How the company organically grew 420% since March 2021, hitting 30% quarter-on-quarter growth in March 2022, and its plans to continue growing exponentially
To stay up to date with Prescient Therapeutics or to receive alerts on company events, please register your details.
Our board
Board
Management
‹
Dr James Campbell
Non-executive director
Dr James Campbell
Non-executive director
Dr Campbell has a solid track record as a scientist and commercial executive with more than 20 years of international biotechnology research, management and leadership experience. He has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies.
Steven Engle
Non-executive chairman
Steven Engle
Non-executive chairman
Steve has over two decades of executive leadership experience with public biotech companies developing breakthrough products in the metabolic, autoimmune, oncologic and infectious disease areas.
Steven Yatomi-Clarke
CEO and managing director
Steven Yatomi-Clarke
CEO and managing director
Steven has overseen Prescient’s progression from start-up phase. He has a distinguished career as an investment banker specialising in the life sciences sector, where he was consistently one of Australia’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments.
Dr Allen Ebens
Non-Executive Director
Dr Allen Ebens
Non-Executive Director
Allen Ebens, Ph.D. brings over twenty four years of drug development experience in oncology and hematology, beginning in drug discovery at Exelixis before moving to Genentech where over 11 years he worked from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and T cell recruiting antibodies.
Dr. Ebens was recruited from Genentech to establish oncology discovery research at Juno Therapeutics (a CAR-T pioneer), and served as Senior Director, Immune Oncology at NGM Biopharmaceuticals.
He is currently Chief Scientific Officer of Vera Therapeutics. Dr. Ebens’ scientific contributions include numerous peer-reviewed publications of original research, a significant patent portfolio, and the advancement of nine discovery projects from initial concept to clinical development for multiple targets including one marketed therapeutic. He completed his PhD at UCLA and postdoctoral training at UCSF.
Melanie Leydin
Chief Financial Officer and Company Secretary
Melanie Leydin
Chief Financial Officer and Company Secretary
Melanie Leydin is a highly experienced CFO and Company Secretary with 25 years of experience in the accounting profession and 15 years of experience in company secretarial services
›
‹
Said Sebti, PhD
Scientific Founder
Said Sebti, PhD
Scientific Founder
- Co-inventor of PTX-100 & PTX-200
- Named among top 20 Translational Researchers in the world by Nature Publishing Group
Terry Chew, M.D.
Chief Medical Officer
Terry Chew, M.D.
Chief Medical Officer
- Hematologist/oncologist with 20 years experience in biotech & pharma
- 5 New Drug Applications including DaunoXome, Taxotere and DepoCyte
- PTX is only 1 of only 2 ASX biotechs with a CMO that has successfully approved drugs
Rebecca Lim, PhD
Senior VP – Scientific Affairs
Rebecca Lim, PhD
Senior VP – Scientific Affairs
- Over 10 years of experience in allogeneic cell therapies for regenerative medicine
- Initiated several first-in-human clinical trials for urgent unmet medical needs based on her research in cell therapies
- Previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University
- Crucial role in the tech transfer, product development and clinical delivery of Malaysia’s first CD19-targeted CAR-T trial.
- Helped develop the RoteaTM Counterflow Centrifugal System for automated CAR-T manufacturing, now sold by Thermo Fisher Scientific
›
Live Investor Briefing
Prescient Therapeutics (ASX: PTX)
Register for an Upcoming Webcast
Please join Prescient CEO and managing director Steven Yatomi-Clarke for an investor briefing.
Steven will discuss:
- Prescient is on the cusp of a significant inflection point
- Why the data from our PTX-100 Phase 1b trial is so promising
- The opportunities available for an effective therapy in T-cell lymphomas, a disease of unmet need
- How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths
- How our $18m cash position allows us to go deep into a Phase 2 trial
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
Can’t make this time, register to receive the replay.
Attend the Session
What is a 708 investor?By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
Please join Prescient CEO and Managing Director Steven Yatomi-Clarke for an investor briefing.
Receive email updates
By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.
